{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:31:54Z","timestamp":1793716314389,"version":"4.6.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lumacaftor\/ivacaftor (LUM\/IVA) is a CFTR modulator approved for the treatment of cystic fibrosis (CF) caused by the F508del mutation. While clinical trials have demonstrated its efficacy, the long-term safety profile remains inadequately characterized. This study aims to assess the real-world safety of LUM\/IVA through a comprehensive analysis of adverse drug events (ADEs) reported in the U. S. FDA Adverse Event Reporting System (FAERS) from the third quarter of 2015 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionality analysis including the reporting odds ratio (ROR) and Bayesian confidence Propagation Neural Network (BCPNN) was employed to identify potential safety signals associated with LUM\/IVA. Furthermore, sensitivity analyses were conducted to eliminate potential confounding arising from concomitant medication use and underlying indications. Potential risk factors for LUM\/IVA-associated depression were identified through logistic regression analysis. Finally, time-to-onset (TTO) analysis was conducted to evaluate the temporal patterns of ADEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 7,843 LUM\/IVA-related ADE reports were extracted, spanning 27 system organ classes (SOCs). We identified 221 positive signals, with 37 signals consistent with the drug label, 61 signals might be associated with disease progression, and 123 signals not listed in the drug label. Positive signals with most reported cases included infective pulmonary exacerbations (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f1,394, ROR 1201.58, IC025 9.50), hospitalization (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f841, ROR 20.07, IC025 4.13) and, dyspnoea (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f517, ROR 4.00, IC025 1.83). Unexpected signals such as depression (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f81, ROR 1.71, IC025 0.45), suicidal ideation (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f31, ROR 1.63, IC025 0.20), and hypoglycemia (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f20, ROR 2.02, IC025 0.39) were detected, highlighting previously unreported risks. Stratified analysis identified risk signals in different subgroups, such as chest discomfort in 50\u2013100\u202fkg subgroup. The TTO analysis revealed that the median onset of ADEs was 256\u202fdays, with most ADEs reports occurring after 360\u202fdays of treatment LUM\/IVA (39.2%), Moreover, cumulative incidence varied significantly among subgroups stratified by age, dosage, and frequency of administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a detailed real-world safety profile of LUM\/IVA, identifying both known and unexpected adverse events. Our findings underscore the importance of continuous post-marketing surveillance and the need for updated drug label to reflect associated risks, particularly those related to psychiatric symptoms and long-term adverse effects. Personalized treatment strategies based on patient characteristics, including sex, are recommended to optimize safety during LUM\/IVA therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1750064","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:46Z","timestamp":1771828246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing safety profile of lumacaftor\/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS"],"prefix":"10.3389","volume":"13","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Tuberculosis, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, Guizhou, China"]},{"name":"Guizhou Provincial Key Laboratory of Pathogenesis and Prevention of Common Chronic Diseases","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"240060","DOI":"10.1183\/16000617.0060-2024","article-title":"Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review","volume":"33","author":"Hansen","year":"2024","journal-title":"Eur Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jcf.2015.05.009","article-title":"Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor","volume":"14","author":"Siracusa","year":"2015","journal-title":"J Cyst Fibros"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/s41598-025-86010-1","article-title":"Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of Lumacaftor Ivacaftor therapy based on real-world data","volume":"15","author":"Imrei","year":"2025","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1113\/JP287289","article-title":"Restoring CFTR function with Orkambi decreases the severity of alcohol-induced acute pancreatitis","volume":"602","author":"Venglovecz","year":"2024","journal-title":"J Physiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del Cftr","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-term safety and efficacy of Lumacaftor-Ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-Cftr mutation: a phase 3, open-label, extension study","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-term safety of Lumacaftor-Ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-Cftr mutation: a multicentre, phase 3, open-label, extension study","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jcf.2019.12.006","article-title":"Lumacaftor\/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease","volume":"19","author":"Tong","year":"2020","journal-title":"J Cyst Fibros"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jcf.2017.02.009","article-title":"Immediate effects of Lumacaftor\/Ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease","volume":"16","author":"Popowicz","year":"2017","journal-title":"J Cyst Fibros"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1513\/AnnalsATS.202402-201OC","article-title":"Long-term impact of lumacaftor\/ivacaftor treatment on cystic fibrosis disease progression in children 2-5 years of age homozygous for F508del-CFTR: a phase 2, open-label clinical trial","volume":"21","author":"Stahl","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/ijc.70059","article-title":"Severe cutaneous adverse reactions associated with novel antiandrogens: a disproportionality analysis of three databases","volume":"157","author":"Zhu","year":"2025","journal-title":"Int J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e33306","DOI":"10.1016\/j.heliyon.2024.e33306","article-title":"Safety assessment of Dapagliflozin: real-world adverse event analysis based on the Faers database from 2012 to 2023","volume":"10","author":"Zhou","year":"2024","journal-title":"Heliyon"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"18175","DOI":"10.1038\/s41598-025-03192-4","article-title":"Analysis and Mining of Brodalumab Adverse Events Based on Faers database","volume":"15","author":"Wan","year":"2025","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2024.2393268","article-title":"Adverse events associated with atogepant: a FAERS-based pharmacovigilance analysis","volume":"24","author":"Zhang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/14740338.2024.2393269","article-title":"A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance data","volume":"24","author":"Zhou","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using Meddra: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.885","article-title":"Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting","volume":"12","author":"Almenoff","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimer's Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph18010114","article-title":"Post-marketing pharmacovigilance of canakinumab from the FDA adverse event reporting system (Faers)","volume":"18","author":"Zhang","year":"2025","journal-title":"Pharmaceuticals"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40360-025-00920-4","article-title":"Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024)","volume":"26","author":"Yang","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14740338.2023.2243220","article-title":"Gender differences in adverse events related to osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (Readus-Pv): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of Lumacaftor\/Ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-Cftr mutation (Progress): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jcf.2020.01.005","article-title":"Unmasking Catamenial hemoptysis in the era of Cftr modulator therapy","volume":"19","author":"Montemayor","year":"2020","journal-title":"J Cyst Fibros"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(15)00234-2","article-title":"Suicide and suicidal behaviour","volume":"387","author":"Turecki","year":"2016","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e49755","DOI":"10.2196\/49755","article-title":"Assessing the labeling information on drugs associated with suicide risk: systematic review","volume":"10","author":"Jeon","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcf.2024.09.020","article-title":"Suicidal behaviour and Cftr modulators: a case series and who database disproportionality analysis","volume":"24","author":"Nidegger","year":"2025","journal-title":"J Cyst Fibros"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"107845","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of Cftr modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J Diabetes Complicat"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1172\/JCI60610","article-title":"Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets","volume":"122","author":"Olivier","year":"2012","journal-title":"J Clin Invest"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1741-7015-12-87","article-title":"Cftr and Anoctamin 1 (Ano1) contribute to camp amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells","volume":"12","author":"Edlund","year":"2014","journal-title":"BMC Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jcf.2025.03.003","article-title":"Immunogenic adverse events to Cftr modulators - an international survey","volume":"24","author":"Urbantat","year":"2025","journal-title":"J Cyst Fibros"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jcf.2023.03.015","article-title":"Drug desensitization to lumacaftor\/ivacaftor: a fast lane to drug tolerance","volume":"22","author":"Westhoff","year":"2023","journal-title":"J Cyst Fibros"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the international depression epidemiological study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"00127","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jcf.2024.09.010","article-title":"Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies","volume":"24","author":"O'Connor","year":"2025","journal-title":"J Cyst Fibros"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from Cftr modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jcf.2014.02.010","article-title":"Depression and anxiety in adolescents and adults with cystic fibrosis in the Uk: a cross-sectional study","volume":"13","author":"Duff","year":"2014","journal-title":"J Cyst Fibros"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1369\/jhc.2009.953455","article-title":"Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain","volume":"57","author":"Guo","year":"2009","journal-title":"J Histochem Cytochem"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.chest.2022.08.2240","article-title":"Sex and gender in lung diseases and sleep disorders: a state-of-the-art review: part 2","volume":"163","author":"Sodhi","year":"2023","journal-title":"Chest"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1900857","DOI":"10.1183\/13993003.00857-2019","article-title":"Fatty airways: implications for obstructive disease","volume":"54","author":"Elliot","year":"2019","journal-title":"Eur Respir J"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e23428","DOI":"10.1016\/j.heliyon.2023.e23428","article-title":"Plasma levels of chemokines decrease during elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"10","author":"Westh\u00f6lter","year":"2024","journal-title":"Heliyon"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/thorax-2024-221634","article-title":"Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by Cftr modulators","volume":"80","author":"Shanthikumar","year":"2025","journal-title":"Thorax"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jcf.2020.12.002","article-title":"Changes in fecal microbiota with Cftr modulator therapy: a pilot study","volume":"20","author":"Pope","year":"2021","journal-title":"J Cyst Fibros"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41590-024-02059-6","article-title":"Integrating single-cell Rna and T\u202fcell\/B\u202fcell receptor sequencing with mass cytometry reveals dynamic trajectories of human peripheral immune cells from birth to old age","volume":"26","author":"Wang","year":"2025","journal-title":"Nat Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3389\/fped.2020.00549","article-title":"Ontogeny related changes in the pediatric liver metabolome","volume":"8","author":"Wilson","year":"2020","journal-title":"Front Pediatr"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"Neha","year":"2021","journal-title":"Hosp Pharm"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (Readus-Pv): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1750064\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:47Z","timestamp":1771828247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1750064\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":56,"alternative-id":["10.3389\/fmed.2026.1750064"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1750064","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1750064"}}